H.C. Wainwright analyst Swayampakula Ramakanth lowered the firm’s price target on Hookipa Pharma to $6.50 from $8 and keeps a Buy rating on the shares post the Q2 report.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on HOOK:
- Hookipa Pharma reports Q2 EPS (22c), consensus (21c)
- HOOKIPA Pharma Reports Second Quarter 2023 Financial Results and Recent Business Highlights
- Is HOOK a Buy, Before Earnings?
- HOOKIPA Pharma to Report Second Quarter 2023 Financial Results and Recent Business Highlights on August 10, 2023
- Biotech Alert: Searches spiking for these stocks today